Aims Although risk scores to predict type 2 diabetes exist, cost-effectiveness of risk thresholds to target prevention interventions are unknown. We applied cost-effectiveness analysis to identify optimal thresholds of predicted risk to target a low-cost community-based intervention in the USA. Methods We used a validated Markov-based type 2 diabetes simulation model to evaluate the lifetime cost-effectiveness of alternative thresholds of diabetes risk. Population characteristics for the model were obtained from NHANES 2001-2004 and incidence rates and performance of two noninvasive diabetes risk scores (German diabetes risk score, GDRS, and ARIC 2009 score) were determined in the ARIC and Cardiovascular Health Study (CHS). Incremental cost...
OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma gl...
OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma gl...
Aims/hypothesis: The cost-effectiveness of screening for diabetes is unknown but has been modelled ...
AimsAlthough risk scores to predict type 2 diabetes exist, cost-effectiveness of risk thresholds to ...
AIMS: To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeti...
AIMS: To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeti...
Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Ob...
Aim To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes that tar...
Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Ob...
Background: Diabetes is a common and costly disease that is expected to continue even to grow in pre...
Background: Diabetes is a common and costly disease that is expected to continue even to grow in pre...
OBJECTIVEdThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma g...
Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Ob...
INTRODUCTION: Treatment thresholds based on risk predictions can be optimized by considering various...
INTRODUCTION: Treatment thresholds based on risk predictions can be optimized by considering various...
OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma gl...
OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma gl...
Aims/hypothesis: The cost-effectiveness of screening for diabetes is unknown but has been modelled ...
AimsAlthough risk scores to predict type 2 diabetes exist, cost-effectiveness of risk thresholds to ...
AIMS: To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeti...
AIMS: To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeti...
Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Ob...
Aim To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes that tar...
Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Ob...
Background: Diabetes is a common and costly disease that is expected to continue even to grow in pre...
Background: Diabetes is a common and costly disease that is expected to continue even to grow in pre...
OBJECTIVEdThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma g...
Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Ob...
INTRODUCTION: Treatment thresholds based on risk predictions can be optimized by considering various...
INTRODUCTION: Treatment thresholds based on risk predictions can be optimized by considering various...
OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma gl...
OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma gl...
Aims/hypothesis: The cost-effectiveness of screening for diabetes is unknown but has been modelled ...